Beneficial drugs for liver diseases
- PMID: 17966118
- DOI: 10.1002/jat.1310
Beneficial drugs for liver diseases
Abstract
Liver diseases are a major problem of worldwide proportions. However, the number of drugs actually used successfully in humans is very small. In this review some of the most promising/studied drugs utilized for liver diseases were chosen and analysed critically from the basic to the clinical point of view. Antiviral agents are not discussed because excellent reviews have appeared on this topic. The compounds/preparations described herein are, alphabetically: colchicine, corticosteroids, curcumin, glycyrrhizin, interferons (for their antifibrotic properties), Liv 52, nitric oxide, resveratrol, silymarin, sulfoadenosylmethionine, and thalidomide. Colchicine and corticosteroids have been studied extensively in animals and humans; most clinical studies suggest that these compounds are not useful in the treatment of liver diseases. Glycyrrhizin is an herbal medicine with several components that has interesting hepatoprotective properties in patients with subacute liver failure but deserves more prospective controlled trials. Interferon has shown interesting antifibrotic properties in animals and humans; prospective studies on their antifibrotic/fibrolytic activity are required. Curcumin, resveratrol and thalidomide are very attractive newly discovered protective and curative compounds on experimental hepatic diseases. Their mechanism of action is associated with the ability to down-regulate NF-kappaB and to decrease pronecrotic and profibrotic cytokines. Unfortunately, clinical studies are lacking. Sulfoadenosylmethionine and silymarin are also promising drugs utilized mainly in cholestasis but the benefits can be expanded if more controlled trials are performed. The future is to carry out controlled prospective double-blind multicenter studies with the newly discovered drugs with proven beneficial effects on animals. Fundamental hepatobiology should also be encouraged.
Similar articles
-
Herbal medicines for liver diseases.Dig Dis Sci. 2005 Oct;50(10):1807-12. doi: 10.1007/s10620-005-2942-9. Dig Dis Sci. 2005. PMID: 16187178 Review.
-
Drug development for liver diseases: focus on picroliv, ellagic acid and curcumin.Fundam Clin Pharmacol. 2008 Dec;22(6):623-32. doi: 10.1111/j.1472-8206.2008.00618.x. Fundam Clin Pharmacol. 2008. PMID: 19049667 Review.
-
Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine.Indian J Med Res. 2006 Nov;124(5):491-504. Indian J Med Res. 2006. PMID: 17213517 Review.
-
Herbal medicine in the treatment of liver diseases.Dig Liver Dis. 2007 Apr;39(4):293-304. doi: 10.1016/j.dld.2006.11.004. Epub 2007 Feb 28. Dig Liver Dis. 2007. PMID: 17331820 Review.
-
Use of herbal supplements for chronic liver disease.Clin Gastroenterol Hepatol. 2004 Nov;2(11):947-56. doi: 10.1016/s1542-3565(04)00455-0. Clin Gastroenterol Hepatol. 2004. PMID: 15551246 Review.
Cited by
-
Hepatoprotective activity of Lepidium sativum seeds against D-galactosamine/lipopolysaccharide induced hepatotoxicity in animal model.BMC Complement Altern Med. 2016 Dec 3;16(1):501. doi: 10.1186/s12906-016-1483-4. BMC Complement Altern Med. 2016. PMID: 27912738 Free PMC article.
-
Antioxidant Activity and Biocompatibility of Fructo-Polysaccharides Extracted from a Wild Species of Ornithogalum from Lebanon.Antioxidants (Basel). 2021 Jan 7;10(1):68. doi: 10.3390/antiox10010068. Antioxidants (Basel). 2021. PMID: 33430440 Free PMC article.
-
Sesamol loaded solid lipid nanoparticles: a promising intervention for control of carbon tetrachloride induced hepatotoxicity.BMC Complement Altern Med. 2015 May 3;15:142. doi: 10.1186/s12906-015-0655-y. BMC Complement Altern Med. 2015. PMID: 25935744 Free PMC article.
-
The Liver Protection Effects of Maltol, a Flavoring Agent, on Carbon Tetrachloride-Induced Acute Liver Injury in Mice via Inhibiting Apoptosis and Inflammatory Response.Molecules. 2018 Aug 23;23(9):2120. doi: 10.3390/molecules23092120. Molecules. 2018. PMID: 30142916 Free PMC article.
-
p-Cymene inhibits pro-fibrotic and inflammatory mediators to prevent hepatic dysfunction.Open Life Sci. 2025 Apr 15;20(1):20221054. doi: 10.1515/biol-2022-1054. eCollection 2025. Open Life Sci. 2025. PMID: 40291773 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical